Last reviewed · How we verify
SC Peginterferon beta-1a
At a glance
| Generic name | SC Peginterferon beta-1a |
|---|---|
| Also known as | Plegridy |
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (PHASE3)
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products (PHASE1)
- Plegridy Satisfaction Study in Participants (PHASE4)
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants (PHASE3)
- Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program
- Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis (PHASE3)
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC Peginterferon beta-1a CI brief — competitive landscape report
- SC Peginterferon beta-1a updates RSS · CI watch RSS
- Biogen portfolio CI